Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

Author： Poyurovsky Michael   Fuchs Camil   Pashinian Artashez   Levi Aya   Faragian Sarit   Maayan Rachel   Gil-Ad Irit  

Publisher： Springer Publishing Company

ISSN： 0033-3158

Source： Psychopharmacology, Vol.192, Iss.3, 2007-06, pp. : 441-448

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

By Cavazzoni P.   Tanaka Y.   Roychowdhury S.M.   Breier A.   Allison D.B.  

European Neuropsychopharmacology, Vol. 13, Iss. 2, 2003-03 ,pp. : 81-85

Elsevier

Access to resources Recommend Favorite

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

By Poyurovsky M.   Koren D.   Gonopolsky I.   Schneidman M.   Fuchs C.   Weizman A.   Weizman R.  

European Neuropsychopharmacology, Vol. 13, Iss. 2, 2003-03 ,pp. : 123-128

Elsevier

Access to resources Recommend Favorite

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol

By Andrezina Raisa   Josiassen Richard   Marcus Ronald   Oren Dan   Manos George   Stock Elyse   Carson William   Iwamoto Taro  

Psychopharmacology, Vol. 188, Iss. 3, 2006-10 ,pp. : 281-292

Springer Publishing Company

Access to resources Recommend Favorite

The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study

By Garcia Esther  

CNS Drugs, Vol. 23, Iss. 7, 2009-07 ,pp. : 615-625

Adis International

Access to resources Recommend Favorite

Nicotine and Behavioral Markers of Risk for Schizophrenia - A Double-Blind, Placebo-Controlled, Cross-Over Study

By Depatie L.   O'Driscoll G.A.   Holahan A.-L.V.   Atkinson V.   Thavundayil J.X.   Kin N.N.Y.   Lal S.  

Neuropsychopharmacology, Vol. 27, Iss. 6, 2002-12 ,pp. : 1056-1070

Elsevier

Access to resources Recommend Favorite